Global Colorectal Cancer Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Adenocarcinomas, Carcinoid Tumors, Lymphomas, Sarcomas, and Gastrointestinal Stromal Tumors (GISTS)), by Diagnosis (Digital Rectal Examination, Fecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, and Others (Biopsy)), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Multispecialty Hospitals, and Cancer Research Centers), Forecast 2022-2028
The global colorectal cancer diagnosis and therapeutics market are anticipated to grow at a CAGR of 4.3% during the forecast period. Colorectal cancer therapeutics is a malignancy that begins in the colon or the rectum, and can likewise be named, colon tumors or rectal cancer depending upon where they begin. The rising prevalence of colorectal cancer due to poor lifestyles such as obesity, consumption of alcohol and tobacco, and lack of physical activity has been the major factor driving the market growth. Colorectal cancer is the fourth leading cause of cancer-related mortalities globally. As per the World Health Organization (WHO), in 2020, the number of deaths of males and females of all ages due to colorectal cancer was around 935,173 across the globe, which is 9.4% of total deaths. And the number of new colorectum cancer patients of both sexes of all ages in 2020 was around 1.9 million globally, which is 10% of new cancer cases. Additionally, as per the WHO, an increase of around 70% in colorectal cancer across the globe is expected by 2030.
Additionally, the increasing geriatric population and rising colorectal cancer associated with them is another factor driving the market growth. Moreover, the high prevalence of smokers and alcohol consumers who are most prone to this cancer has been boosting the market. For instance, as per the Centers for Disease Control and Prevention, in 2019, around 14 of every 100 US adults of age 18 years or above smoked cigarettes, which is 14% or 34.1 million adults. High cost of screening tests and treatment along with low awareness of this cancer act as major restraints for the market growth. However, ongoing improvements in healthcare expenditure, technological advancement for cancer treatment, and rising demand for colorectal cancer diagnosis and therapeutics are expected to drive the market in developing countries.
Impact of COVID-19 Pandemic on Global Colorectal Cancer Diagnosis and Treatment Market
The global colorectal cancer diagnosis and treatment market is hit by the outbreak of COVID-19 since December 2019. It has a sudden and dramatic impact on healthcare. Initially in Italy, screening for colorectal cancer (CRC) was forcefully suspended. The colorectal cancer diagnosis and therapies market has declined especially in the first half of 2020. The pandemic has had an impact on how people function and how different surgical procedures are performed. The number of cancer surgeries has significantly declined during the pandemic, due to the strict guidelines by the regulatory authorities to avoid all non-emergent surgeries. The outbreak of COVID-19 has disrupted the supply of raw materials and products across the globe.
As doctors frontline warriors fighting against COVID-19, all other treatment procedures were postponed except emergency cases. The COVID-19 pandemic shows severe symptoms in people, who are already suffering from chronic disease. This has impacted that people did not visit the hospital not to get exposed to the virus. To fight the pandemic the key players were focusing on the manufacturing of chemicals for sanitizers, and donated methylene diphenyl diisocyanate (MDI) to enable the manufacture of prefabricated polyurethane insulation panels for hospital construction and other materials to manufacture personal protective equipment (PPE) for medical personnel fighting the coronavirus. The market will witness “V” shape recovery in near future owing to the restart of key industries in major economies.
The global colorectal cancer diagnosis and therapeutics market are segmented based on type, diagnosis, treatment, and end-user. Based on the type, the market is segmented into adenocarcinomas, carcinoid tumors, lymphomas, sarcomas, and gastrointestinal stromal tumors (GISTS). Based on the diagnosis, the market is segmented into digital rectal examination, fecal occult blood test, flexible sigmoidoscopy, colonoscopy, and others diagnoses. Based on the treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Apart from this, by end-users, the market is segmented into multispecialty hospitals and cancer research centers.
Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Treatment, 2020 (%)
Global Colorectal Cancer Diagnosis and Therapeutics Market Share by Treatment
Surgery Segment holds the significant share in the Market
Among the treatment for colorectal cancer, the surgery segment held the highest share in 2020 and is also anticipated to grow during the forecast period. Surgery is used for early-stage cancers, and the type of surgery depends on the stage of cancer. It is a medical specialty that uses operative instruments on a person to treat a disease or injury, to improve bodily function, or to repair unwanted ruptured areas. Surgery is done for the removal of the tumor and some surrounding healthy tissue during an operation. This is known as surgical resection. Surgery is the most common and widely used treatment for colorectal cancer. During surgery, a part of the healthy colon or rectum and nearby lymph nodes to be removed. When the colon cancer is very small then minimally invasive surgery will be done such as removing polyps during a colonoscopy (polypectomy), endoscopic mucosal resection, and laparoscopic surgery. The factors such as rising quality assessment in hospitals, growing colorectal cancer cases among individuals, and increasing demand for minimal complication rates in surgery of special colorectal cancer are anticipating the market growth during the forecast period.
The global colorectal cancer diagnosis and therapeutics market are further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others, and the Rest of the World (the Middle East and Africa, and Latin America). North America has been predicted to dominate the global colorectal cancer diagnosis and therapeutics market due to well-established health infrastructure, development in technology, support from the government, and high prevalence of this cancer towards people. For instance, as per the American Cancer Society, around 104,270 new cases of colon cancer and around 45,230 new cases of rectal cancer are expected in the US in 2021.
Global Colorectal Cancer Diagnosis and Therapeutics Market Growth, by Region 2022-2028
Global Colorectal Cancer Diagnosis and Therapeutics Market Growth, by Region
Asia-Pacific is projected to have a considerable growth in the global colorectal cancer diagnosis and therapeutics market
Asia-Pacific is anticipated to have a considerable growth in the global colorectal cancer diagnosis and therapeutics market. The rising geriatric population, increasing incidence and prevalence rate of colorectal cancer are the factors that are growing the market demand in the region. As per the report of WHO, in 2020, in the Asia-pacific region, around 569,186 incidences of colon cancer were recorded, which is 49.6% of total cases across the globe. The reason for more new cases of cancers and mortalities is having a huge population base in the region. Besides, around 296,236 mortalities were recorded due to colon cancer in 2020, which was around 51.4%.
Market Players Outlook
The key players of the colorectal cancer diagnosis and therapeutics market include Abbott Diagnostics, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Beckman Coulter, F.Hoffmann-La Roche Ltd, Quest Diagnostics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2020, IMV Inc., an immunology company, announced the collaboration with The Wistar Institute. This collaboration was done for the development of a targeted T cell therapy against the BRAF cancer mutation, based on the peptides. This gene’s mutations are the most common cancer-causing mutation in melanoma and have also been seen in colorectal cancer, thyroid cancer, and others.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global colorectal cancer diagnosis and therapeutics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
Table of Contents
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Automotive Battery Market
- Recovery Scenario of Global Automotive Battery Market
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
5.1.1. Lead Acid Battery
5.1.2. Lithium-Ion Battery
5.2. Global Automotive Battery Market by Fuel Type
5.2.1. Internal Combustion (IC) Engine Vehicle
5.2.2. Electric Vehicle
5.3. Global Automotive Battery Market by Vehicle Type
5.3.1. Passenger Cars
5.3.2. Commercial Vehicles
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7.2. Acumuladores Moura SA
7.3. BYD Co. Ltd.
7.4. C&D Technologies Inc.
7.5. CSB Enetrgy Technology Co. Ltd
7.6. EAST PENN Manufacturing Co.
7.8. EXIDE Technologies
7.9. First National Battery
7.10. GS Yuasa Corp.
7.11. Hitachi Ltd.
7.13. Northstar Battery
7.14. Panasonic Corp.
7.15. Robert Bosch GmBH
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Bayer AG
- Beckman Coulter, Inc.
- Boehringer Ingelheim International GmbH
- Clinical Genomics Technologies Pvt. Ltd.
- EDP Biotech Corp.
- Epigenomics AG
- Eli Lilly and Co.
- Exact Sciences Corp.
- Genomictree Co., Ltd.
- IMV Inc.
- ISA Pharmaceuticals B.V.
- Merck & Co., Inc.
- Metabiomics Corp.
- Quest Diagnostics Inc.,
- Randox Laboratories Ltd
- F.Hoffmann-La Roche Ltd
- Siemens Healthcare Pvt. Ltd.
- Taiho Pharmaceutical Co., Ltd.
- VolitionRX Ltd.